BioCryst (BCRX) | Financial Analysis & Statements
BioCryst Pharmaceuticals Inc. Mid-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
406.6M
Gross Profit
397.0M
97.66%
Operating Income
260.4M
64.05%
Net Income
245.8M
60.47%
Balance Sheet Metrics
Total Assets
514.2M
Total Liabilities
633.3M
Shareholders Equity
-119.2M
Cash Flow Metrics
Operating Cash Flow
270.7M
Free Cash Flow
291.2M
Revenue & Profitability Trend
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
BioCryst Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 874.8M | 450.7M | 331.4M | 270.8M | 157.2M |
| Cost of Goods Sold | 19.1M | 12.5M | 4.7M | 6.6M | 7.3M |
| Gross Profit | 855.8M | 438.2M | 326.8M | 264.2M | 149.9M |
| Gross Margin % | 97.8% | 97.2% | 98.6% | 97.6% | 95.4% |
| Operating Expenses | |||||
| Research & Development | 166.1M | 174.6M | 216.6M | 253.3M | 208.8M |
| Selling, General & Administrative | 348.6M | 266.1M | 213.9M | 159.4M | 118.8M |
| Other Operating Expenses | - | - | - | - | - |
| Total Operating Expenses | 514.8M | 440.8M | 430.5M | 412.7M | 327.6M |
| Operating Income | 341.0M | -2.5M | -103.7M | -148.4M | -177.7M |
| Operating Margin % | 39.0% | -0.6% | -31.3% | -54.8% | -113.1% |
| Non-Operating Items | |||||
| Interest Income | 10.7M | 14.7M | 15.8M | 5.1M | 62.0K |
| Interest Expense | 78.9M | 98.5M | 108.2M | 99.1M | 59.3M |
| Other Non-Operating Income | -5.4M | -641.0K | -30.1M | -2.0M | 55.1M |
| Pre-tax Income | 267.4M | -87.0M | -226.2M | -244.4M | -181.8M |
| Income Tax | 3.5M | 1.9M | 310.0K | 2.7M | 2.3M |
| Effective Tax Rate % | 1.3% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Income | 263.9M | -88.9M | -226.5M | -247.1M | -184.1M |
| Net Margin % | 30.2% | -19.7% | -68.4% | -91.2% | -117.1% |
| Key Metrics | |||||
| EBITDA | 365.1M | 13.4M | -86.3M | -141.9M | -176.9M |
| EPS (Basic) | $1.26 | $-0.43 | $-1.18 | $-1.33 | $-1.03 |
| EPS (Diluted) | $1.21 | $-0.43 | $-1.18 | $-1.33 | $-1.03 |
| Basic Shares Outstanding | 209893000 | 206696000 | 192198000 | 185908000 | 179117000 |
| Diluted Shares Outstanding | 209893000 | 206696000 | 192198000 | 185908000 | 179117000 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
BioCryst Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 89.7M | 104.7M | 110.6M | 304.8M | 504.4M |
| Short-term Investments | 185.0M | 216.1M | 278.3M | 119.5M | 3.2M |
| Accounts Receivable | 106.8M | 79.1M | 57.0M | 50.6M | 29.4M |
| Inventory | 5.4M | 8.1M | 28.7M | 27.5M | 15.8M |
| Other Current Assets | 17.2M | 13.8M | 19.5M | 12.6M | 10.0M |
| Total Current Assets | 404.3M | 422.0M | 496.0M | 516.5M | 566.1M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 15.8M | 18.2M | 5.6M | 4.6M | 10.7M |
| Goodwill | - | - | - | - | - |
| Intangible Assets | - | - | - | - | - |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 29.7M | 28.3M | 13.1M | 6.8M | 6.5M |
| Total Non-Current Assets | 109.8M | 68.5M | 21.0M | 33.5M | 22.0M |
| Total Assets | 514.2M | 490.4M | 517.0M | 550.0M | 588.2M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 15.8M | 11.6M | 20.9M | 14.4M | 27.8M |
| Short-term Debt | 1.6M | 2.8M | 2.6M | 2.4M | 1.8M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 52.2M | 32.7M | 23.6M | - | - |
| Total Current Liabilities | 196.1M | 160.4M | 150.0M | 105.5M | 103.7M |
| Non-Current Liabilities | |||||
| Long-term Debt | 437.2M | 806.0M | 822.5M | 739.1M | 591.4M |
| Deferred Tax Liabilities | - | - | - | - | - |
| Other Non-Current Liabilities | - | - | - | - | - |
| Total Non-Current Liabilities | 437.2M | 806.0M | 822.5M | 739.1M | 591.4M |
| Total Liabilities | 633.3M | 966.4M | 972.5M | 844.6M | 695.1M |
| Equity | |||||
| Common Stock | 2.1M | 2.1M | 2.1M | 1.9M | 1.8M |
| Retained Earnings | -1.5B | -1.8B | -1.7B | -1.5B | -1.2B |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | -119.2M | -475.9M | -455.5M | -294.6M | -107.0M |
| Key Metrics | |||||
| Total Debt | 438.9M | 808.7M | 825.1M | 741.5M | 593.2M |
| Working Capital | 208.3M | 261.6M | 346.0M | 411.0M | 462.4M |
Balance Sheet Composition
BioCryst Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 263.9M | -88.9M | -226.5M | -247.1M | -184.1M |
| Depreciation & Amortization | 1.4M | 1.2M | 1.7M | 1.4M | 777.0K |
| Stock-Based Compensation | 80.8M | 65.4M | 55.6M | 44.7M | 34.6M |
| Working Capital Changes | -49.1M | -89.2M | -25.6M | -56.4M | 11.1M |
| Operating Cash Flow | 327.8M | -43.9M | -108.6M | -157.5M | -83.3M |
| Investing Activities | |||||
| Capital Expenditures | -2.5M | -1.1M | -2.2M | -1.4M | -2.4M |
| Acquisitions | -6.2M | - | - | - | - |
| Investment Purchases | -262.2M | -266.8M | -514.4M | -244.3M | -10.0M |
| Investment Sales | 256.6M | 320.5M | 385.1M | 117.4M | 28.2M |
| Investing Cash Flow | -13.7M | 52.6M | -131.5M | -128.2M | 15.8M |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | 0 | 0 | 300.0M | 73.1M | 293.9M |
| Debt Repayment | -302.0M | -1.7M | -241.6M | 0 | 0 |
| Financing Cash Flow | -359.0M | -9.2M | 24.1M | 146.3M | 637.8M |
| Free Cash Flow | 344.9M | -53.1M | -97.3M | -163.2M | -144.5M |
| Net Change in Cash | -45.0M | -468.0K | -216.0M | -139.4M | 570.3M |
Cash Flow Trend
BioCryst Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
7.09
Forward P/E
10.70
Price to Book
-15.53
Price to Sales
2.46
PEG Ratio
-0.01
Profitability Ratios
Profit Margin
30.16%
Operating Margin
65.60%
Return on Equity
-221.45%
Return on Assets
43.22%
Financial Health
Current Ratio
2.06
Debt to Equity
-4.01
Beta
0.69
Per Share Data
EPS (TTM)
$1.21
Book Value per Share
$-0.56
Revenue per Share
$4.17
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| BCRX | 2.2B | 7.09 | -15.53 | -221.45% | 30.16% | -4.01 |
| Zoetis | 49.8B | 19.58 | 15.04 | 65.99% | 28.24% | 279.59 |
| Haleon Plc - ADR | 42.4B | 18.72 | 1.88 | 10.27% | 15.11% | 52.37 |
| Alkermes plc | 5.6B | 23.71 | 3.09 | 14.72% | 16.37% | 3.85 |
| Lantheus Holdings | 5.4B | 24.30 | 4.91 | 21.45% | 15.15% | 57.19 |
| Amneal | 4.2B | 63.23 | -57.42 | -101.02% | 2.39% | 45,095.52 |
Financial data is updated regularly. All figures are in the company's reporting currency.






